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Main results
Probiotics reduced CDAD and did not differ for adverse events compared with placebo or no treatment (Table) . Subgroup analyses showed no differences in effect for adults and children, lower and higher doses of probiotics, low and high or unclear risk for bias, or single and multiple probiotic species (all interaction P > 0.05).
Conclusion
In adults or children receiving antibiotic treatment, probiotics reduce Clostridium difficile-associated diarrhea. 
Source

Commentary
CDAD can cause morbidity and mortality, and treatment is challenging; this makes prevention appealing. Probiotics are not new-deliberate administration of harmless bacteria and fungi has been used for years to prevent antibiotic-induced diarrhea, but this approach has not been universally embraced by the medical community.
Using probiotics with antibiotics seems counterintuitive as the antibiotics could inactivate the preventive agent. The efficacy of probiotics has been difficult to confirm due to small study sizes and nonstandard probiotic dosing. More recently, 3 factors have reduced some skepticism: a consistent 40% to 60% reduction in CDAD with probiotics in individual trials, the increasing challenge of treating CDAD, and the dramatic benefit of stool infusion in refractory CDAD (1) . Before this review by Johnston and colleagues, lingering suspicion about probiotic trials was based on frequent sponsorship by probiotic manufacturers, secular changes in CDAD epidemiology, and possible publication bias.
Johnston and colleagues found no significant evidence of publication bias. Although the 20 RCTs were imperfect, with many lacking allocation concealment or missing participant data, the conclusion of benefit with probiotics was supported even with a worst-case scenario for missing data. The case definition of CDAD was reasonable for the period of the studies but might be altered in subsequent trials. Whether there is a difference among the specific probiotic agents or doses is still an unanswered question.
Clinicians need to know whether use of probiotics with an antibiotic prescription has benefits. The answer, I believe, is a cautious yes. While the NNT of about 30 means that the practitioner may not personally see a dramatic reduction in CDAD, the low cost and apparent safety of probiotics supports their use, at a minimum, in patients with a desire to use them or in those at high risk for CDAD. Other patients can be informed about the risks and benefits and can decide for themselves. Future studies should compare different probiotic regimens and doses and confirm safety and tolerability. Ideally, new trials could suggest the optimal agent for various age groups, underlying disease, and other factors.
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